Recent advances in delivery of peptide and protein therapeutics to the brain .

The classes of neuropharmaceuticals known as proteins and peptides serve as diagnostic tools and are involved in specific communication in the peripheral and central nervous systems (CNS). However, due to tight junctions resembling epithelial cells found in the blood-brain barrier (BBB) ​​in vivo, they are typically excluded from transport from the blood to the brain. The drugs having molecular weight of less than 400 Dalton are able to cross the BBB via lipid-mediated free diffusion. However, large molecule therapeutics are devoid of these characteristics. As an alternative, these substances may be carried via chimeric peptide drug delivery systems, and assist in transcytosis through BBB with the aid of linker strategies. With their recent developments, several forms of nanoparticles, including PEG-PCL, nanogels, liposomes, NLCs, PLGA-NPs, chitosan, and SLNs, have also been considered for their therapeutic applications. Moreover, the necessity for physiological optimization of current drug delivery methods and their carriers to deliver therapeutic doses of medication into the brain for the treatment of various neurological illnesses has also been emphasized. Therapeutic use of proteins and peptides has no neuroprotective impact in the absence of all these methods. Each tactic, however, has unique drawbacks and considerations. In this review, we discuss different drug delivery methods for therapeutic distribution of pharmaceuticals, primarily neuroproteins and neuropeptides, through endothelial capillaries via blood-brain barrier. Finally, we have also discussed challenges and future perspective of protein and peptide therapeutics delivery to the brain Significance Statement Very few reports on the delivery of therapeutic protein and peptide nanoformulations are available in the literature. Herein, we attempted to discuss these nanoformulations of protein and peptide therapeutics used to treat brain diseases. <!--EndFragment -->.